PM
ADMA icon

Prosight Management’s ADMA Biologics ADMA Stock Holding History

Prosight Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-115,100
Closed -$184K – 44
2021
Q2 		$184K Sell
115,100
-382,742
-77% -$673K 0.12% 46
2021
Q1 		$876K Sell
497,842
-385,372
-44% -$882K 0.72% 30
2020
Q4 		$1.72M Buy
883,214
+347,890
+65% +$731K 0.8% 28
2020
Q3 		$1.28M Sell
535,324
-763,976
-59% -$2.09M 0.61% 38
2020
Q2 		$3.81M Buy
1,299,300
+56,600
+5% +$163K 1.63% 22
2020
Q1 		$3.58M Buy
+1,242,700
New +$4.3M 1.67% 21
2019
Q4 		– Sell
-548,409
Closed -$2.44M – 40
2019
Q3 		$2.44M Buy
548,409
+362,688
+195% +$1.52M 1.35% 25
2019
Q2 		$719K Buy
+185,721
New +$820K 0.36% 34

Other funds holding ADMA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Prosight Management's ADMA Position: Q3 2021 in Review

Prosight Management sold out of ADMA Biologics (ADMA) in Q3 2021, closing a stake of 115,100 shares — an estimated $184K sold.

Prosight Management first reported a position in ADMA in Q2 2019 and held it in 8 quarters. The position peaked at $3.81M in Q2 2020. 72 funds tracked by Wall St. Rank hold ADMA as of Q3 2021.

  • Prosight Management reported no remaining ADMA Biologics position as of Q3 2021 after selling out during the quarter.
  • Prosight Management sold 115,100 ADMA Biologics shares in Q3 2021, an estimated $184K.
  • Prosight Management first reported a position in ADMA Biologics in Q2 2019 and held it in 8 quarters.
  • Prosight Management's ADMA Biologics position peaked at $3.81M in Q2 2020.
  • 72 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2021.

Based on Prosight Management's 13F filing for Q3 2021, filed 12 Nov 2021.